Senior Investigator, Head of "Virus-Cell Interactions" Laboratory, Lady Davis Institute for Medical Research
Professor Department of Medicine, Division of Experimental Medicine; Department of Microbiology and Immunology, McGill University
Dr. Gatignol’s Publications Indexed on PubMed
Dr. Anne Gatignol obtained a Pharmacist diploma and PhD in Microbiology from the University of Toulouse, France. She completed a first post-doctoral training in the department of Biochemistry at the George Washington University, Washington, DC, USA and a second at the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. She worked as a researcher at the Institut National de la santé et de la recherche médicale and the Cochin Institute, Paris, France. Now a senior investigator at the Lady Davis Institute for Medical Research, and full Professor at McGill University, her current focus is on various aspects of virology and molecular biology, specifically as applied to virus-cell interactions and to the development of RNA therapeutics against the human immunodeficiency virus (HIV) and SARS-Cov-2.
Major Research Activities
Dr. Gatignol’s research focuses on the control of the cellular responses to HIV infection, which enhance or inhibit viral replication. She characterized several cellular factors that contribute to the regulation of PKR during HIV replication in lymphocytes and astrocytes. Her work continues with the characterization of this regulation in primary lymphoid and myeloid cells that are the natural targets for HIV.
Dr. Gatignol’s lab also studies the interactions between viruses and the components of the RNA interference machinery. She characterized the relationship between TRBP and Dicer proteins in the RNA-induced silencing complex. She is analyzing the modifications of the RNAi pathway induced by the HIV, Zika and SARS-CoV-2 viruses and their pathological consequences.
Dr. Gatignol’s lab also develops RNA-based technologies to target HIV, SARS-CoV-2 and their cellular cofactors to inhibit viral replication. The aim of this project is to use the active anti-HIV molecules expressed on a lentiviral vector for use in gene therapy and to develop RNA therapeutics against SARS-CoV-2 to be used intransally as an antiviral treatment.
Recent Publications
Chen MJ, Gatignol A,
Scarborough RJ. The discovery and development of RNA-based therapies for
treatment of HIV-1 infection. Expert Opin. Drug Discov. 2023. 18:163-179.
Alpuche-Lazcano
SP, Saliba J, Costa VV, Campolina-Silva GH, Marim FM, Ribeiro LS, Blank V, Mouland AJ, Teixeira MM, Gatignol A.
Profound downregulation of neural transcription factor Npas4 and Nr4a family in
fetal mice neurons infected with Zika virus. PLoS Negl. Trop. Dis. 2021. 1: e0009425.
Goguen
RP, Del Corpo O, Malard CMG, Daher A, Alpuche-Lazcano SP, Chen MJ, Scarborough
RJ, Gatignol A. Efficacy, accumulation and transcriptional profile of anti-HIV
shRNAs expressed from human U6, 7SK and H1 promoters. Mol. Ther. Nucleic Acids.
2021. 23:1020-1034.
Del Corpo O, Goguen RP, Malard
CMG, Daher A, Colby-Germinario S, Scarborough RJ, Gatignol A. A U1i RNA that
enhances HIV-1 splicing with elongated recognition domain is an optimal
candidate for combination HIV-1 gene therapy. Mol. Ther. Nucleic Acids. 2019. 18:815-830.
Radetskyy
R, Daher A, Gatignol A. ADAR1 and PKR, interferon stimulated genes with
clashing effects on HIV-1 replication. Cyt. Growth Factors Rev. 2018. 40:48-58.